Literature DB >> 11464280

Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27.

Y W Zhang1, I Morita, M Ikeda, K W Ma, S Murota.   

Abstract

Many lines of evidence indicate that connexin genes expressing gap junction (GJ) proteins inhibit tumor cell proliferation. However, the precise molecular mechanisms remain unclear. In this study, we show that overexpression of connexin43 (Cx43) suppressed proliferation of human osteosarcoma U2OS cells through inhibition of the cell cycle transition from G1 to S phase. This inhibition was attributed to a significant accumulation of the hypophosphorylated retinoblastoma (Rb) protein, which was causally related to decreases in the kinase activities of cyclin-dependent kinases (CDKs) 2 and 4. Enforced Cx43 expression markedly increased the level of the CDK inhibitor p27. This increase resulted from an increased synthesis and a reduced degradation of the p27 proteins, but not influence of the p27 mRNA. Moreover, we show that the Cx43-modulated GJ function was the main contributor to the elevation in p27 levels, in which cAMP was involved. These data suggest that Cx43 appears to inhibit proliferation of U2OS cells by increasing the levels of p27 proteins via post-transcriptional regulatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464280     DOI: 10.1038/sj.onc.1204563

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

Review 1.  Gap junction- and hemichannel-independent actions of connexins.

Authors:  Jean X Jiang; Sumin Gu
Journal:  Biochim Biophys Acta       Date:  2004-10-22

2.  In differentiating prefusion myoblasts connexin43 gap junction coupling is upregulated before myoblast alignment then reduced in post-mitotic cells.

Authors:  Aniko Gorbe; David L Becker; Laszlo Dux; Laszlo Krenacs; Tibor Krenacs
Journal:  Histochem Cell Biol       Date:  2005-12-10       Impact factor: 4.304

3.  Pericyte chemomechanics and the angiogenic switch: insights into the pathogenesis of proliferative diabetic retinopathy?

Authors:  Jennifer T Durham; Brian M Dulmovits; Stephen M Cronk; Anthony R Sheets; Ira M Herman
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-06       Impact factor: 4.799

4.  Human articular chondrocytes express multiple gap junction proteins: differential expression of connexins in normal and osteoarthritic cartilage.

Authors:  Maria D Mayan; Paula Carpintero-Fernandez; Raquel Gago-Fuentes; Oskar Martinez-de-Ilarduya; Hong-Zhang Wang; Virginijus Valiunas; Peter Brink; Francisco J Blanco
Journal:  Am J Pathol       Date:  2013-02-13       Impact factor: 4.307

5.  Downregulation of calbindin 1, a calcium-binding protein, reduces the proliferation of osteosarcoma cells.

Authors:  Zhengxiang Huang; Guojun Fan; Dongliang Wang
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

6.  Regulation of vascular smooth muscle proliferation by heparin: inhibition of cyclin-dependent kinase 2 activity by p27(kip1).

Authors:  Stephen Fasciano; Rekha C Patel; Indhira Handy; Chandrashekhar V Patel
Journal:  J Biol Chem       Date:  2005-02-24       Impact factor: 5.157

Review 7.  Gap junction and hemichannel-independent actions of connexins on cell and tissue functions--an update.

Authors:  Jade Z Zhou; Jean X Jiang
Journal:  FEBS Lett       Date:  2014-01-14       Impact factor: 4.124

8.  Altered tumor biology and tumorigenesis in irradiated and chemical carcinogen-treated single and combined connexin32/p27Kip1-deficient mice.

Authors:  Timothy J King; Paul D Lampe
Journal:  Cell Commun Adhes       Date:  2005 Jul-Dec

Review 9.  Cell-cell communication in the osteoblast/osteocyte lineage.

Authors:  Roberto Civitelli
Journal:  Arch Biochem Biophys       Date:  2008-04-11       Impact factor: 4.013

10.  Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer.

Authors:  Imre Romics; Gergely Bánfi; Eszter Székely; Tibor Krenács; Béla Szende
Journal:  Pathol Oncol Res       Date:  2008-04-16       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.